2020
A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants
Abdallah CG, Ahn KH, Averill LA, Nemati S, Averill CL, Fouda S, Ranganathan M, Morgan PT, D’Souza D, Mathalon DH, Krystal JH, Driesen NR. A robust and reproducible connectome fingerprint of ketamine is highly associated with the connectomic signature of antidepressants. Neuropsychopharmacology 2020, 46: 478-485. PMID: 32967000, PMCID: PMC7852889, DOI: 10.1038/s41386-020-00864-9.Peer-Reviewed Original ResearchConceptsConnectome fingerprintN-methyl-d-aspartate modulatorsNovel rapid-acting antidepressantsMajor depressive disorder patientsMechanism of antidepressantsWeeks of sertralineRapid-acting antidepressantsMagnetic resonance imaging studyDepressive disorder patientsExecutive networkEffects of ketamineLongitudinal functional magnetic resonance imaging studyResonance imaging studyFunctional magnetic resonance imaging studyBrain functional connectivityCohort AIntravenous infusionSubanesthetic doseClinical trialsNormal salineDisorder patientsConnectomics signaturesBrain circuitryKetamineImaging studies
2015
Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine
Ahn KH, Sewell A, Elander J, Pittman B, Ranganathan M, Gunduz-Bruce H, Krystal J, D'Souza DC. Role of GABA Deficit in Sensitivity to the Psychotomimetic Effects of Amphetamine. Neuropsychopharmacology 2015, 40: 2822-2831. PMID: 25953357, PMCID: PMC4864658, DOI: 10.1038/npp.2015.132.Peer-Reviewed Original ResearchConceptsGABA deficitHealthy subjectsPsychotomimetic effectsIntravenous infusionSchizophrenia patientsPANSS positive symptoms subscaleDouble-blind crossover designStriatal dopamine releasePositive symptom subscaleAdministration of drugsDose of AMPHPartial inverse agonistSubclinical responsePharmacokinetic interactionsSubthreshold doseDopamine releaseBenzodiazepine receptorsSymptom subscalesCrossover designCADSS scoresPositive symptomsAMPHInverse agonistSubjective effectsTest day
2007
Psychiatric safety of ketamine in psychopharmacology research
Perry EB, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O’Donnell E, Krystal JH, D’Souza D. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology 2007, 192: 253-260. PMID: 17458544, DOI: 10.1007/s00213-007-0706-2.Peer-Reviewed Original ResearchConceptsSubanesthetic dosesHealthy human subjectsKetamine administrationClinical research programHuman subjectsTest sessionsPsychotic spectrum disordersPsychiatric safetyResidual sequelaePlacebo infusionIntravenous infusionKetamine effectsPsychopharmacology studiesResultsFour hundredAdverse reactionsObjectiveTo reportHealthy subjectsStudy participationClinical investigationHealthy humansSide effectsKetamineInfusionDosesAdministration
2002
Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms
Abi-Saab W, Seibyl JP, D'Souza C, Karper LP, Gueorgueva R, Abi-Dargham A, Wong ML, Rajhans S, Erdos JP, Heninger GR, Charney DS, Krystal JH. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology 2002, 162: 55-62. PMID: 12107618, DOI: 10.1007/s00213-002-1057-7.Peer-Reviewed Original ResearchConceptsReceptor antagonismSchizophrenic patientsNeuroleptic-free schizophrenic patientsBrief Psychiatric Rating ScaleDouble-blind conditionsPsychiatric Rating ScaleTest dayRitanserin pretreatmentIntravenous infusionReceptor modulationAntipsychotic activityMale inpatientsReceptor stimulationPlasma prolactinCortisol levelsSchizoaffective disorderSchizophrenia symptomsPositive symptomsNegative symptomsRandomized orderPatientsRating ScaleBehavioral activationSymptomsRitanserinImpact of intravenous nicotine on BOLD signal response to photic stimulation
Jacobsen LK, Gore JC, Skudlarski P, Lacadie CM, Jatlow P, Krystal JH. Impact of intravenous nicotine on BOLD signal response to photic stimulation. Magnetic Resonance Imaging 2002, 20: 141-145. PMID: 12034334, DOI: 10.1016/s0730-725x(02)00494-0.Peer-Reviewed Original ResearchConceptsBOLD signal responseFunctional magnetic resonance imagingPhotic stimulationIntravenous infusionNeuronal activitySuccessive intravenous infusionsBlood oxygen level-dependent (BOLD) signalEffects of nicotineLevel-dependent signalMagnetic resonance imagingHealthy smokersVascular effectsTobacco smokingBrain effectsNicotine receptorsIntravenous nicotineEvidence of alterationsOccipital cortexVisual cortexResonance imagingNicotineBOLD signalStimulationInfusionCortex
1997
Noradrenergic and Serotonergic Function in Posttraumatic Stress Disorder
Southwick SM, Krystal JH, Bremner JD, Morgan CA, Nicolaou AL, Nagy LM, Johnson DR, Heninger GR, Charney DS. Noradrenergic and Serotonergic Function in Posttraumatic Stress Disorder. JAMA Psychiatry 1997, 54: 749-758. PMID: 9283511, DOI: 10.1001/archpsyc.1997.01830200083012.Peer-Reviewed Original ResearchConceptsYohimbine-induced panic attacksPosttraumatic stress disorderPanic attacksCardiovascular effectsCardiovascular measurementsStress disorderYohimbine hydrochloridePTSD symptomsDiastolic blood pressureDouble-blind fashionSeparate test daysGreater increaseBlood pressureIntravenous infusionSerotonergic functionNoradrenergic activitySerotonergic systemNoradrenergic systemHealthy subjectsSerotonergic activityPatientsDifferent patientsTest dayCombat veteransYohimbineEvidence of acoustic startle hyperreflexia in recently detoxified early onset male alcoholics: modulation by yohimbine and m-Chlorophenylpiperazine (mCPP)
Krystal J, Webb E, Grillon C, Cooney N, Casal L, Morgan III. C, Southwick S, Davis M, Charney D. Evidence of acoustic startle hyperreflexia in recently detoxified early onset male alcoholics: modulation by yohimbine and m-Chlorophenylpiperazine (mCPP). Psychopharmacology 1997, 131: 207-215. PMID: 9203230, DOI: 10.1007/s002130050285.Peer-Reviewed Original ResearchConceptsHealthy subjectsAcoustic startle responseEthanol withdrawalStartle responseStartle magnitudeStartle amplitudeRandomized orderAcoustic startle magnitudeChronic alcoholic patientsSerotonin partial agonistDouble-blind conditionsAcoustic startle amplitudeNumber of episodesMale healthy subjectsΑ2-adrenergic antagonistTest dayMale patientsPlacebo dayAlcoholic patientsIntravenous infusionNoradrenergic functionYohimbine effectAlcohol detoxificationDrug infusionPreclinical studies
1996
Serotonergic and noradrenergic dysregulation in alcoholism: m- chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects
Krystal JH, Webb E, Cooney NL, Kranzler HR, Southwick SW, Heninger GR, Charney DS. Serotonergic and noradrenergic dysregulation in alcoholism: m- chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. American Journal Of Psychiatry 1996, 153: 83-92. PMID: 8540598, DOI: 10.1176/ajp.153.1.83.Peer-Reviewed Original ResearchConceptsHealthy comparison subjectsAlcoholic patientsComparison subjectsCortisol responseYohimbine infusionPostsynaptic noradrenergic receptorsBlood pressure responseDouble-blind conditionsNoradrenergic reactivitySaline placeboNoradrenergic receptorsMHPG levelsIntravenous infusionYohimbine effectMHPG responsePlasma levelsNoradrenergic systemPersistent alterationsNoradrenergic dysregulationMale inpatientsDrug effectsNeuroendocrine responsivityPatientsPhysiologic responsesPlasma cortisolContinuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796.
Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796. Journal Of Nuclear Medicine 1996, 37: 11-5. PMID: 8543979.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntipsychotic AgentsBenzamidesBrainContrast MediaCorpus StriatumDopamine AntagonistsDose-Response Relationship, DrugFeasibility StudiesHumansInfusions, IntravenousIodine RadioisotopesMalePiperazinesPyrrolidinesReceptors, DopamineReceptors, Dopamine D2Time FactorsTomography, Emission-Computed, Single-PhotonConceptsHealthy male subjectsContinuous infusionBrain activity levelsReceptor occupancyStriatal activityAntipsychotic agentsDopamine receptorsMale subjectsSerial venous blood samplesSide effect ratingsBrain time-activity curvesContinuous intravenous infusionExtrapyramidal side effectsStriatal dopamine receptorsVenous blood samplesDopamine receptor occupancySerial SPECT imagesClinical responseExtrapyramidal symptomsIntravenous infusionSerum prolactinAntipsychotic drugsBlood samplesSide effectsTime-activity curves
1995
Effects of the benzodiazepine antagonist flumazenil in PTSD
Randall P, Bremner J, Krystal J, Nagy L, Heninger G, Nicolaou A, Charney D. Effects of the benzodiazepine antagonist flumazenil in PTSD. Biological Psychiatry 1995, 38: 319-324. PMID: 7495926, DOI: 10.1016/0006-3223(94)00306-n.Peer-Reviewed Original ResearchConceptsVisual analogue rating scaleAdministration of flumazenilAnxiety symptomsCrossover study designBenzodiazepine antagonist flumazenilGABAA receptor complexBenzodiazepine/GABAA receptor complexPanic disorder patientsAnalogue rating scalesFlumazenil administrationPTSD Symptom ScaleIntravenous infusionAntagonist flumazenilGABAA antagonistHealthy controlsClinical studiesDisorder patientsSymptom ScaleFlumazenilPanic disorderPanic attacksVietnam combat veteransStudy designRating ScalePTSD symptoms
1994
Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms
Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS. Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms. JAMA Psychiatry 1994, 51: 898-911. PMID: 7944878, DOI: 10.1001/archpsyc.1994.03950110058008.Peer-Reviewed Original ResearchConceptsVisual analog scaleAnalog scaleScale scoreVisual analog scale scoreYohimbine hydrochlorideAnalog scale scoreDouble-blind conditionsEffect of mCPPReceptor partial agonistEffects of ethanolNoradrenergic mechanismsIntravenous infusionPlasma levelsSerotonergic systemNoradrenergic systemPlaceboDiscriminative propertiesMale inpatientsYohimbinePlasma prolactinCortisol levelsPartial agonistSerotonergic contributionAlcohol dependenceDays of testing